NCT07601997尚未招募不适用
Clinical Application Study on the Safety and Feasibility of Transcatheter Injectable Protein Alginate-based Hydrogel for Alleviating Reperfusion Injury in Acute STEMI
Myomed Technology (Shaoxing) Co., Ltd.1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2026年5月30日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
- 试验地点
- 1
研究概览
简要总结
The purpose of this clinical trial is to preliminarily evaluate the safety and feasibility of the transcatheter injectable protein alginate-based hydrogel developed and manufactured by Myomed Technology (Shaoxing) Co., Ltd. in alleviating reperfusion injury in acute STEMI. This is a randomized controlled trial with a blank control group (conventional PCI treatment). A total of 20 patients will be enrolled in a 1:1 ratio into the test group and the control group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 to 80 years;
- •Diagnosed with first-onset acute anterior wall ST-segment elevation myocardial infarction (STEMI), requiring primary percutaneous coronary intervention (PCI) and stent implantation;
- •Ischemic symptoms (e.g., chest pain, precordial discomfort) persist for >30 minutes, and electrocardiographic findings meet the following criteria: ST-segment (J-point) elevation ≥1.0 mm (i.e., amplitude 0.1 mV) in all conventional leads except leads V2 and V
- •For leads V2 and V3, the ST-segment elevation criteria are: ≥2.5 mm in males <40 years old, ≥2.0 mm in males ≥40 years old, and ≥1.5 mm in females of all ages;
- •The time interval from the onset of ischemic symptoms to the first PCI balloon dilation is ≤12 hours;
- •Admission coronary angiography shows that the left anterior descending artery (LAD) has a TIMI flow grade of 0 (complete occlusion), and the TIMI flow grade reaches 3 after stent implantation;
- •Able to understand the purpose of the trial, voluntarily participate in the study, sign the informed consent form personally or via a legal representative, and be willing to complete the follow-up in accordance with the protocol requirements.
排除标准
- •Complicated with cardiogenic shock or cardiac arrest; or complicated with acute myocardial infarction mechanical complications requiring surgical or interventional intervention (e.g., ventricular septal perforation, papillary muscle rupture, free wall rupture), or complicated with giant left ventricular aneurysm;
- •Previously diagnosed with hypertrophic cardiomyopathy, hemodynamically significant congenital heart disease, severe valvular heart disease, chronic cor pulmonale, chronic heart failure, or with a history of cardiac tamponade, pericarditis, or myocarditis;
- •History of previous myocardial infarction, coronary intervention (PCI), or coronary artery bypass grafting (CABG);
- •Cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 3 months;
- •Heart failure severity at admission reaches Killip classification Grade III or above;
- •Complicated with malignant arrhythmia, complete atrioventricular block, or new-onset complete left bundle branch block (LBBB);
- •Diagnosed or suspected aortic dissection;
- •Diabetes mellitus with severe complications;
- •Complicated with atrial fibrillation and receiving only warfarin treatment, or with a high bleeding risk;
- •Received thrombolytic therapy prior to PCI;
- •Diameter of the infarct-related artery < 2 mm or abundant coronary collateral circulation in the risk area;
- •Coronary angiography indicates diffuse vascular lesions or severe calcification that may affect the absorption of protein alginate-based hydrogel;
- •Severe complications (e.g., coronary artery rupture, perforation, or stent dislodgement) occurring during PCI;
- •Received coronary bioresorbable stent implantation;
- •Complicated with severe acute infection requiring systemic treatment;
- •Currently diagnosed with malignant tumor or receiving malignant tumor treatment;
- •Severe autoimmune disease requiring therapeutic intervention;
- •History of severe anemia (hemoglobin < 60 g/L) or thrombocytopenia (platelet count < 100×10⁹/L);
- •Known renal insufficiency (including estimated creatinine clearance < 30 ml/min/1.73 m², or receiving treatment for severe renal insufficiency);
- •Alanine aminotransferase (ALT) level exceeding 3 times the upper limit of normal, with the investigator judging clinically significant liver dysfunction;
- •Known allergy to the study product or any radiocontrast agent;
- •Contraindications to cardiovascular magnetic resonance (CMR) examination (e.g., implanted cardiac pacemaker, implantable cardioverter-defibrillator, nerve stimulator, cerebral aneurysm clip, cochlear implant, or claustrophobia);
- •Cognitive dysfunction, dementia, or severe mental illness;
- •Currently participating in other clinical trials and have not yet reached the primary endpoint;
- •Expected survival period < 1 year due to comorbidities;
- •Pregnant or lactating women, or fertile subjects who do not take effective medical contraceptive measures during the study period;
- •Other factors that the investigator deems may have a significant impact on result judgment or the safety and efficacy of the subjects.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Versius Gynecology StudyNCT07289295CMR Surgical Ltd46
尚未招募
1 期
UGX202 Injection in Patients With Advanced Retinitis PigmentosaNCT07311863Suzhou UgeneX Therapeutics Co., Ltd.6
尚未招募
1 期
Phase I Clinical Study of NouvNeu001 Injection for the Treatment of Moderate-to-Advanced Parkinson's Disease in Patients Who Have Previously Undergone Deep Brain Stimulation or Deep Brain Nucleus Lesioning SurgeryParkinson's Disease (PD)NCT07550374iRegene Therapeutics Co., Ltd.10
尚未招募
1 期
Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell MalignanciesRelapsed/Refractory B-Cell MalignanciesNCT07493174Institute of Hematology & Blood Diseases Hospital, China86
招募中
不适用
Clinical trial to evaluate the efficacy and safety of PTFE-coated biliary stentsResectable or borderline resectable pancreatic cancer requiring biliary drainagejRCT106225009840